ASCO is coming up, so there will be major-league oncology news next week. But some of it couldn’t wait, so…
Wyeth’s new drug (Torisel) for kidney cancer gets the OK from the FDA.
Novartis expecting big things from Glivec/Gleevec and the next generation, Tasigna. Speaking of Novartis, a good (long-ish) article on the company research strategy.
Some late-stage failures: another stroke drug bites the dust (Forest Labs), and an Actos combo (Takeda) is shelved.
Problem drugs: a summary of the sketchy stuff behind the scenes in the ramp-up to Ketek approval (Aventis), and more commentary on the Avandia issue – focusing on the potentially high negative impact of knee-jerk cessation of treatment.
While on the subject of diabetes – a helpful article summarizing the various classes of treatment, and the spillover effect of the Avandia problems for Takeda’s Actos (which is getting a bunch of new prescriptions).
Finally, Xyzal, son of Zyrtec, approved for allergy treatment.
——-
Might be news to you – 30 minutes
Leave a Reply